

IN THE CLAIMS:

Please cancel claims 4-6, 8, 9, 13-30 and 51-79, without prejudice.

Please amend claims 7, 10 and 11 to read as follows:

- A¹
7. (Amended) A solid pharmaceutical dosage form for enhanced systemic delivery of irinotecan comprising irinotecan and a gastric retention vehicle composition comprising a hydrogel, wherein the dosage form expands upon contact with gastric fluid and wherein after ingestion by a patient the gastric retention vehicle composition expands to retain the dosage form in the patient's stomach for a prolonged period of time.

- A²
10. (Amended) A method of inhibiting cell proliferation in a tumor of a patient afflicted with meta-static carcinoma of the colon or rectum by orally administering a dosage form of claim 7 to the patient.

11. (Amended) A method of inhibiting cell proliferation in a tumor of a patient afflicted with meta-static carcinoma of the colon or rectum by executing a therapeutic program of repeated oral administration of dosage forms of claim 7 to the patient.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "**Version with Markings to Show Changes Made.**"